Managing the Stomach Side Effects of GLP-1 Weight Loss Drugs: What You Need to Know | Research

The takeaway

Up to 84% of patients on GLP-1 and related peptide weight loss drugs experience gastrointestinal side effects like nausea and diarrhea, but strategies like slow dose increases and dietary changes can help manage them.

65–84% GI adverse event rate
Across patients treated with liraglutide, semaglutide, or tirzepatide for obesity, with nausea and diarrhea being the most common — primarily due to altered gastric motility

What the researchers found

Gastrointestinal adverse effects occur in 65–84% of patients treated with incretin-based anti-obesity medications (liraglutide, semaglutide, tirzepatide), with nausea and diarrhea being the most common. These symptoms are primarily caused by altered gastric motility and hormone-mediated changes in appetite signaling. Preventive strategies including slow dose titration, dietary counseling, and supportive medications can improve tolerability and treatment continuation.

Why it matters

GLP-1 receptor agonists and dual GLP-1/GIP agonists are transforming obesity treatment, but their high rates of GI side effects are a major barrier to adherence. Up to 84% of patients experience these symptoms, and many discontinue treatment as a result. Understanding the mechanisms and management of these side effects is critical for clinicians to maximize the long-term success of these peptide-based therapies.

The numbers in context

65–84% GI adverse event rate · Liraglutide, semaglutide, tirzepatide · Most common: nausea, diarrhea · Also: constipation, GERD, cholelithiasis · 2006–2025 literature review

How the study worked

Literature review searching PubMed and Scopus for articles published 2006–2025. Included randomized controlled trials, observational studies, and narrative/systematic reviews reporting GI adverse effects in obesity treatments, with focus on incretin-based anti-obesity medications.

Who was studied

Review of GI adverse effects in patients receiving obesity treatments, particularly incretin-based anti-obesity medications

What this study cannot tell us

As a narrative review, it synthesizes existing evidence without meta-analytic pooling. GI symptom reporting varies across trials, making direct comparisons difficult. The review focuses on published trial data, which may underrepresent real-world GI side effect severity and impact on quality of life. Management strategies discussed are largely based on clinical experience and guidelines rather than randomized evidence.

How to read the evidence

This is a narrative literature review synthesizing data from randomized controlled trials, observational studies, and prior reviews. The GI adverse event rates cited come from high-quality clinical trials, but the management strategies are largely based on clinical consensus and guidelines rather than randomized comparisons.

When this study was published

Published in 2025, this review is highly current and reflects the clinical experience accumulated since the widespread adoption of semaglutide and tirzepatide for obesity treatment.

The bigger picture

As millions of people worldwide start taking GLP-1 and dual agonist peptide drugs for obesity, managing GI side effects is becoming one of the most important practical challenges in clinical medicine. These side effects are the primary reason patients discontinue treatment, potentially undermining the enormous public health benefits of effective obesity pharmacotherapy. Developing better management protocols — and potentially designing next-generation peptide drugs with improved GI tolerability — is a major focus of the field.

Questions still open

Can next-generation incretin-based drugs be designed with reduced GI side effects while maintaining weight loss efficacy?
Do GI side effects diminish over time with continued treatment, or do they persist long-term in some patients?
Are there biomarkers that could predict which patients will experience severe GI adverse effects before starting treatment?

Common questions

Why do GLP-1 drugs cause nausea and stomach problems?

GLP-1 receptor agonists work partly by slowing down how fast food moves through your stomach (gastric emptying), which helps you feel full longer and eat less. But this slowing also triggers nausea, bloating, and other stomach discomfort — essentially, food sits in the stomach longer than the body expects. The drugs also affect appetite signaling hormones throughout the digestive tract, which can cause diarrhea or constipation.

Will the side effects go away over time?

For many patients, GI side effects are most intense during the first few weeks of treatment or when the dose is increased, and they gradually improve as the body adjusts. This is why doctors recommend starting at a low dose and increasing slowly. However, some patients continue to experience symptoms throughout treatment, and about 5–10% discontinue due to GI intolerance.

Read the original research

Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies.

Biomedicines, 13(10)

View on PubMed ↗Publisher’s paper ↗

Citation

Witaszek, Tomasz; Biesiada, Aleksander; Iskra-Trifunović, Joanna; Babicki, Mateusz; Mastalerz-Migas, Agnieszka; Kłoda, Karolina. (2025). Gastrointestinal Symptoms in Obesity Therapy: Mechanisms, Epidemiology, and Management Strategies.. Biomedicines, 13(10). https://doi.org/10.3390/biomedicines13102362